SCHEMBL6002300

SCHEMBL6002300

Cc1ccc(NCCS)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
HTT P42858 3/20 0.47
HRH3 Q9Y5N1 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 2/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 2/20 0.44
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
BLM P54132 1/20 0.44
PLEC Q15149 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065837 0.85 MAPT (1.00) MAPTHTTHRH3MEN1KMT2A
SCHEMBL8020304 0.85 MAPT (0.64) MAPTHTTHRH3MEN1KMT2A
Hydrochloric Acid SCHEMBL15329323 0.82 MAPT (0.94) MAPTHTTHRH3MEN1KMT2A
SCHEMBL11518048 0.80 MAPT (0.80) MAPTHTTHRH3MEN1KMT2A
SCHEMBL409332 0.78 MAPT (0.76) MAPTHTTHRH3MEN1KMT2A
SCHEMBL11516786 0.78 IDO1 (0.44) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL11521297 0.78 MAPT (0.85) MAPTHTTHRH3MEN1KMT2A
SCHEMBL13650793 0.78 MAPT (0.76) MAPTHTTHRH3MEN1KMT2A
SCHEMBL11520411 0.78 MAPT (0.85) MAPTHTTHRH3MEN1KMT2A
SCHEMBL81430 0.77 MAPT (0.67) MAPTHTTHRH3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116572617-A Packaging structure and method for enhancing thermal conduction between thermal interface material and soaking plate interface 长沙安牧泉智能科技有限公司 2023-08-11 CN disclosed
US-10675355-B2 VAR2CSA-drug conjugates VAR2 PHARMACEUTICALS APS (DK) 2020-06-09 US disclosed
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2019-09-05 US disclosed
EP-2968440-B1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS INC (CA) 2019-06-05 EP disclosed
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2019-02-12 US disclosed
US-20180117163-A9 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC. (CA) 2018-05-03 US disclosed
US-20180117163-A9 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC. (CA) 2018-05-03 US disclosed
US-20170246310-A1 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC. (CA) 2017-08-31 US disclosed
US-20170246310-A1 VAR2CSA-DRUG CONJUGATES ZYMEWORKS INC. (CA) 2017-08-31 US disclosed
US-20170029490-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES ZYMEWORKS INC. (CA) 2017-02-02 US disclosed
US-9522876-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2016-12-20 US disclosed
US-9522876-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same ZYMEWORKS INC. 2016-12-20 US disclosed
WO-2015095953-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2015-07-02 WO disclosed
WO-2015095952-A1 VAR2CSA-DRUG CONJUGATES THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2015-07-02 WO disclosed
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2014-10-23 US disclosed
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS BC INC. (CA) 2014-10-23 US disclosed
US-20060199917-A1 thermoplastic elastomer exhibiting high recyclability and oil resistance as well as excellent mechanical strength, and in particular, excellent resistance to compression set is provided. The thermoplastic resin with epoxy, hydroxy or nitrogen groups in backbone YOKOHAMA RUBBER CO., LTD., THE (JP) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170246310-A1 VAR2CSA-DRUG CONJUGATES VARS1, GUSB, VAV1 MAPT 2887/4885HTT 2385/4885HRH3 1422/4885
US-20140315954-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, CCNB2, CCNB3 MAPT 1616/4885HTT 3286/4885HRH3 617/4885
US-10675355-B2 VAR2CSA-drug conjugates VARS1, GUSB, VAV1 MAPT 2887/4885HTT 2385/4885HRH3 1422/4885
US-20180117163-A9 VAR2CSA-DRUG CONJUGATES VARS1, GUSB, VAV1 MAPT 2887/4885HTT 2385/4885HRH3 1422/4885
US-10201614-B2 Cytotoxic and anti-mitotic compounds, and methods of using the same CCNB1, PLK1, CCNB2 MAPT 692/4885HTT 2394/4885HRH3 2142/4885
US-20190269785-A1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME CCNB1, PLK1, BOD1L1 MAPT 838/4885HTT 2521/4885HRH3 2056/4885
US-20170029490-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES MPST, TPST2, SULT1A1 MAPT 212/4885HTT 2162/4885HRH3 3261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.